The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
You are here: Home / Archives for COVID-19

Antibodies to Watch in a Pandemic

August 26, 2020 by The Antibody Society

The extraordinary scale of the COVID-19 pandemic has elicited extraordinary responses world-wide, but the resulting disruptions have raised concerns about delays in approval of non-COVID-19 antibody therapeutics.

As part of the virtual Antibody Engineering & Therapeutics Europe conference, Dr. Janice Reichert, Executive Director of The Antibody Society,  provided an update on non-COVID-19 antibody therapeutics approved so far in 2020, and those that might be approved by the end of the year. She also discussed the biologics currently in development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics.

Broadcast date: Thursday August 27, 2020.

Updated presentation slides can be downloaded here.

Dataset of commercially sponsored biologic COVID-19 interventions can be downloaded here.

Filed Under: Approvals, Coronavirus, COVID-19, European Medicines Agency, Food and Drug Administration Tagged With: antibody therapeutics, approved antibodies, COVID-19, European Medicines Agency, Food and Drug Administration

FDA issues Emergency Use Authorization for COVID-19 convalescent plasma

August 24, 2020 by Janice Reichert

On August 23, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for investigational COVID-19 convalescent plasma (CCP) for the treatment of COVID-19 in hospitalized patients. CCP is human plasma collected by FDA-registered blood establishments from individuals whose plasma contains anti SARS-CoV-2 antibodies, and who meet all donor eligibility requirements and are qualified. Titer levels of anti-SARS-CoV-2 antibodies are determined by the Ortho VITROS SARS-CoV-2 IgG test before units of CCP are released. Units found to have a signal-to-cutoff ratio of 12 or greater qualify as High Titer COVID-19 Convalescent Plasma.

Based on scientific evidence available, the FDA concluded CCP may be effective in treating COVID-19, and that the known and potential benefits of CCP outweigh the known and potential risks of the product. The EUA authorizes the distribution of COVID-19 convalescent plasma in the U.S. and its administration by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients with COVID-19.

Data obtained from the ongoing National Convalescent Plasma Expanded Access Protocol (EAP) sponsored by the Mayo Clinic was included in FDA assessment. This uncontrolled, single-arm study was established in April 2020 to provide access to COVID-19 convalescent plasma in hospitalized subjects with severe or life-threatening COVID-19 or judged by the treating provider to be at high risk of progression to severe or life-threatening disease. As of August 13, 2020, over 90,000 patients have been enrolled. Data from the EAP posted online on August 12, 2020 reveals trends toward reduced mortality when patients receive CCP with higher antibody levels and at earlier time points. According to FDA’s decision memorandum:

  • In the subset of non-intubated patients, there was a 21% reduction in 7-day mortality (from 14% to 11%, p=0.03) in subjects transfused with high versus low titer CCP.
  • In the subgroup of patients less than 80 years of age who were not intubated and who were within 72 hours of diagnosis, a significant reduction in 7-day mortality from 11.3 to 6.3% (p = 0.0008) was observed when titers are binned to low versus high.
  • Survival trends observed at 7 days persisted over a longer time period, with significantly improved survival in non-intubated patients (p=0.032) and a larger benefit in the subset of patients not intubated at the time of treatment, less than 80 years of age, who were treated within 72 hours of diagnosis (p=0.0081)

However, there was no difference in 7-day survival in the overall population between subjects transfused with high versus low titer CCP, and there was no apparent association between neutralizing antibody titers and 7-day mortality in intubated subjects.

Information from the EUA and clinical studies of CCP may inform the development of other biologic COVID-19 interventions, such as recombinant anti-SARS-CoV-2 antibodies.  The Antibody Society is currently tracking 10 such antibodies in clinical studies or with clinical studies pending. We will report on the progress of these molecules and other COVID-19 interventions in the future.

Filed Under: COVID-19, Food and Drug Administration Tagged With: convalescent plasma, COVID-19, Food and Drug Administration

SARS-CoV2, COVID-19 and the Cytokine Storm

August 18, 2020 by The Antibody Society

Written by Damani Bryant, Bio-Techne

The advent of a global pandemic.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has infected over 18 million people globally, as of August 2020. Of those infected, more than 700,000 people have been killed by coronavirus disease 2019 (COVID-19). Our current understanding is that the crisis began with several cases of pneumonia in Wuhan, China in early December 2019 (1). The World Health Organization (WHO) declared COVID-19 a public health emergency of international concern on January 30, 2020. COVID-19 was subsequently declared a pandemic by the WHO Director General on March 11. By August 2020, the WHO-documented distribution of COVID-19 infections is as follows: 9.9+ million cases in the Americas, 3+ million cases in Europe, 2+ million in South-East Asia, 1.5+ million cases in the Eastern Mediterranean, 800,000+ cases in Africa, and 300,000+ cases in the Western Pacific.

COVID-19 symptoms

Efforts to contain SARS-CoV2 are stymied by the fact that many of the infected are asymptomatic. One study estimates that up to 45% of those infected are asymptomatic (2). Symptomatic individuals have an onset between 2 and 14 days after exposure to the virus (3).  Relatively mild symptoms described by the  Centers for Disease Control (CDC) include: fever, chills, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headaches, loss of the sense of smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea. More severe responses to infection can progress from cytokine release syndrome (CRS), also known as the “cytokine storm”, to acute respiratory distress syndrome (ARDS), multiorgan failure, and death. CRS is thought to be an important step in the progression to ARDS in SARS-CoV2, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections (1,4). The clinical presentation of CRS ranges from mild fever, arthralgia, myalgia to high fever, uncontrolled systemic inflammatory responses, vascular leakage to disseminated intravascular coagulation and organ failure among other symptoms (5).  ARDS is formally defined as a respiratory failure within a week of a known insult that is characterized by bilateral opacities that are not fully explained by cardiac function or volume overload, effusion (fluid buildup), lung collapse, nodules and oxygenation below a specific threshold (6).  The death rate associated with ARDs is 40%.

Biology of SARS-CoV2 and COVID-19

SARS-CoV2 is a member of the Coronaviridae family, specifically the Coronavirinae subfamily that includes 4 genera: α-coronavirus, β-coronavirus, γ-coronavirus and δ-coronavirus (7). SARS-CoV2, SARS-COV and MERS-CoV are all RNA β coronaviruses. SARS-CoV2 shares 80% sequence identity with SARS-COV and 50% sequence identity with MERS-CoV (1,8). SARS-COV emerged from China in 2002 and spread globally, infecting over 8,000 and killing more than 700 people (8,9). MERS-CoV emerged from Saudi Arabia in 2012 and was responsible for over 2,000 infections and over 800 deaths globally (9). All three coronaviruses cause severe respiratory disease in humans. Although the SARS-CoV2 symptoms are milder and the mortality rate is thought to be lower (~3%-6.7%) than SARS-CoV (9.6%) and MERS-CoV (35%), it has a faster transmission rate in humans (7,8,10).

SARS-CoV2 and SARS-CoV enter cells via the angiotensin-converting enzyme-related carboxypeptidase (ACE2) receptor, which is expressed on cardiopulmonary and hematopoietic tissues. (1,11-13). SARS-CoV2 has been reported to have a 10-20 times higher binding affinity for ACE2 than SARS-CoV (7). Receptor-mediated viral entry requires priming of the S1 region of the viral spike (S) by the transmembrane serine protease 2 (TMPRSS2) (8,11,12). The S1 region of the viral spike binds to ACE2 followed by S2 subunit-mediated fusion of the viral and cellular membrane. After membrane fusion, ACE2 and SARS-CoV2 are endocytosed into the cell. SARS-CoV2 internalization has been correlated with increased production of proinflammatory cytokines such as nuclear factor kappa B (NF-κB) and interleukin 6 (IL-6) (8).  IL-6 signals through a cis signaling pathway and a trans signaling pathway (13). The cis signaling pathway involves the binding of IL-6 to a complex containing IL-6 receptor (IL-6R) and glycoprotein 130 (gp130). This stimulates the downstream activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3 (JAK/STAT3) pathway. Activation of this pathway can promote CRS via activation of innate  and acquired immune mechanisms, including T cell differentiation and B cell activation and differentiation. In the trans signaling pathway, IL-6 forms a complex with soluble IL-6R and gp130 on many cell membranes due to the gp130’s ubiquitous expression. This propagates the CRS-stimulating signal to cells that do not express membrane IL-6R. Other cytokines and growth factors that are altered  in response to the trans signaling pathway include increased vascular endothelial growth factor (VEGF), monocyte chemoattractant protein 1 (MCP-1), IL-8, and decreased E-Cadherin in endothelial cells (13). As alluded to previously, CRS is characterized by the release of excessive amount of proinflammatory cytokines such as interferons, interleukins, chemokines, Colony stimulating factors, and tumor necrosis factor alpha, that are harmful to the host (8). Quantitative real time PCR studies of intensive care unit COVID-19 patients have documented elevated transcripts of a variety of cytokines including:  IL-2, IL-7, IL-10, G-CSF, IP-10,  MIP-1A, TNF  and CXCL-8 (14).

Methods for assessing the cytokine storm

A National Cancer Institute scale is commonly used to grade the severity of CRS in patients (5).  Other scales include: the Penn Grading Scale, Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Lee et.al, 2014 and the MD Anderson Cancer Center (MDACC) scale (15). Grade 1 is characterized by fever. Symptoms are mild and not life threatening. Symptoms may or may not require treatment depending on the scale used. Grade 2 is characterized by hypotension that is responsive to fluids or low dose vasopressors. Symptoms are more moderate at this stage and may require hospitalization. All scales suggest an intervention. Organ toxicities may also be observed at this stage. Grade 3 is characterized by hypotension that requires high dose vasopressors, hypoxia and organ toxicities. Symptoms are more severe at this stage and require more aggressive interventions. Finally, grade 4 CRS is severe enough to require ventilation. CRS complications at this grade are life threatening.

Efficacy of COVID-19 therapeutic candidates

Circulating IL-6 has been correlated with COVID-19 severity in patients (16). Given the prominent role of IL-6, it is no surprise that tocilizumab, a human monoclonal anti-IL-6R antibody has been administered to patients with severe COVID-19 (17). Tocilizumab is approved for the treatment of CRS triggered by CAR T cell therapy by the Food and Drug Administration (13). Early data indicated that tocilizumab is associated with a shorter duration of vasomotor support and ventilation, shorter median time to recovery, improvement in CRS grade and computerized tomography imaging results in COVID-19 patients (17, 18). However, more recent data from Phase 3 clinical trials indicate that the human IL-6R antibodies tocilizumab and sarilumab are not associated with an overall benefit in COVID-19 patients. The Phase 3 sarilumab trial was recently halted because it failed to reach primary and secondary endpoints (19). A Phase 3 (global randomized, double blind, placebo controlled) tocilizumab trial was also halted because it failed to meet its primary endpoint of improved clinical status in patients hospitalized with severe COVID-19 pneumonia (20).

The corticosteroid dexamethasone, which is known for its anti-inflammatory and immunosuppressive effects, has recently been shown to reduce the mortality of COVID-19 patients on ventilators by one-third according to preliminary data presented to the WHO (21). Dexamethasone is now recommended standard of care for “patients with COVID-19 who are mechanically ventilated and in patients with COVID-19 who require supplemental oxygen but who are not mechanically ventilated” (22,23).  However, like tocilizumab, the anti-malarial drug hydroxychloroquine has fallen out of favor and clinical trials have been halted due to lack of efficacy (24).  As of mid-August 2020, there are over 3,000 COVID-19-related studies listed on the clinicaltrials.gov website, suggesting many other interventions are still being evaluated. Taken together, the rapid global transmission and high mortality rate of those infected underscores the urgent need to understand COVID’s mechanism of action and quickly pivot when a vaccine or therapeutic candidate is not efficacious.

References

  1. Coperchini, F. et al. (2020) The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 53:25
  2. Oran, D. P. and E. J. Topal (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection A Narrative Review Ann Internal Med. [Epub ahead of print]
  3. Laur, S. A. et al. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Int Med. 172:577
  4. Channappanavar, R. and S. Perlman (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 39:529
  5. Shimabukuro-Vornhagen, A. et al. (2018) Cytokine release syndrome.  J. Immunotherapy of Cancer. 6:56
  6. Matthay, M. A. et al. (2019) Acute Respiratory Distress Syndrome. Nat. Rev. Disease Primers. 5:18
  7. Fani, M. et al. (2020) Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virol. [Epub ahead of print]
  8. Hirano, T and M. Murakami (2020) COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 52:731
  9. Lu, R. et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395:565
  10. Perlman, S. (2020) Another Decade, Another Coronavirus. N Engl J Med. 382:760
  11. Zhou, P. et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Epub ahead of print].
  12. Hoffmann, M. et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [Epub ahead of print]
  13. Moore, J. B. and C. H. June (2020) Cytokine release syndrome in severe COVID-19. Science 368:6490
  14. Huang, C. et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497
  15. Liu, D. and J. Zhao (2018) Cytokine release syndrome: grading, modeling, and new therapy. J Hemat & Oncol. 11:121
  16. Ulhaq, Z. S. and G. V. Soraya (2020) Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 50:382
  17. Kewan, T. et al. (2020) Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E Clinical Med. [Epub ahead of print]
  18. Mastroianni, A. et al. (2020) Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study. E Clinical Med. [Epub ahead of print]
  19. https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30-00
  20. https://www.roche.com/media/releases/med-cor-2020-07-29.htm
  21. https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients
  22. https://www.sciencemag.org/news/2020/07/one-uk-trial-transforming-covid-19-treatment-why-haven-t-others-delivered-more-results
  23. https://www.covid19treatmentguidelines.nih.gov/dexamethasone/
  24. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19

Filed Under: COVID-19 Tagged With: COVID-19, cytokine storm, SARS-CoV-2

Register for the AIRR-C COVID-19 Special Event!

August 17, 2020 by Pam Borghardt

Leveraging AIRR-sequencing data to inform the Biology of COVID-19

The AIRR Community is pleased to announce a 3-day special event focused on AIRR-sequencing data and COVID-19. Due to the unprecedented nature of the COVID-19 pandemic and the need for rapid scientific progress, this virtual meeting will provide recent analyses of the B- and T-cell receptor repertoires of COVID-19 patients. In addition, we will explore a key objective of the AIRR Community in the context of the pandemic: How the scientific response to the COVID-19 pandemic might be leveraged to promote the implementation of standards for AIRR-seq data.

Tuesday – Thursday, September 8th – 10th, 8:00 – 11:00 PDT / 11:00 AM – 2:00 PM EDT / 5:00 – 8:00 PM CEST

Full event details found here.

Register Now!!

Filed Under: AIRR Community, Coronavirus, COVID-19 Tagged With: Adaptive Immune Receptor Repertoire Community

Emergency Use Authorization requested for leronlimab

August 15, 2020 by Janice Reichert

On August 12, 2020, Cytodyn requested that the Food and Drug Administration grant an Emergency Use Authorization for leronlimab for mild to moderate COVID-19 based on data from the Phase 2 CD10 study (NCT04343651). In this study, patients were randomized to receive weekly doses of 700 mg leronlimab or placebo, both of which were administered via subcutaneous injection. Top-level results of the study showed that, in patients with Total Clinical Symptom Scores of ≥ 4 at baseline (higher scores equate to poorer health state), at Day 3, more subjects treated with leronlimab reported improvement in total clinical symptom score compared to the placebo group (90% on leronlimab arm vs. 71% on placebo). The EUA request was disclosed in an investment community conference call that will be available until September 12, 2020.

  • Leronlimab is a humanized IgG4 antibody targeting C-C chemokine receptor type 5.

Filed Under: COVID-19 Tagged With: antibody therapeutics, clinical, COVID-19, Emergency Use Authorization, Food and Drug Administration, leronlimab

« Previous Page
Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III Starts Tomorrow! May 20, 2025
  • Exciting news – The AIRR Community is turning 10! 🎂 May 8, 2025
  • The Antibody Society (TAbS): Win a FREE Attendance Pass to AET Basel & Present A Poster: Call For Abstracts! March 26, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals